share_log

Matinas BioPharma | 10-K: FY2022 Annual Report

SEC ·  Mar 15, 2023 13:02
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more